Abstract
Introduction Despite the proven benefits of reperfusion therapies in acute ischemic stroke, treatment decisions in the hyperacute phase remain complex and are rarely supported by individualized outcome predictions. Artificial intelligence (AI)-based clinical decision support systems (CDSS) offer potential real-time prognostic estimates, but prospective evidence of their feasibility and performance in routine clinical workflows is limited. Our aim is to prospectively evaluate real-time feasibility, usability, and predictive performance of an AI-based CDSS (VALIDATE-CDSS) for individualized outcome prediction in acute stroke care.
Methods and analysis Prospective, multicenter, observational study enrolling consecutive patients with acute ischemic stroke presenting to three tertiary stroke centers. Clinical management will follow standard practice at the discretion of treating physicians. In parallel, a dedicated researcher will collect patient data in real time and input them into the VALIDATE-CDSS using a mobile application, operating in shadow mode without influencing clinical decisions. The system will generate individualized predictions of 3-month functional outcome (modified Rankin Scale) for four treatment strategies (intravenous thrombolysis, endovascular thrombectomy, combined therapy, or no reperfusion) at three sequential time points: baseline clinical data, non-contrast CT, and CT angiography.
The primary outcome is the real-world feasibility and usability of the VALIDATE-CDSS in the hyperacute stroke workflow. Secondary outcomes include predictive performance, agreement between model-suggested and actual treatments, incremental value with increasing data availability, and assessment of potential bias across predefined subgroups. This study will provide prospective real-world evidence on the implementation and clinical potential of AI-based decision support for personalized treatment selection in acute ischemic stroke
Ethics and dissemination Patient enrollment began after approval from the ethics committees of all participating centers. Results will be disseminated through peer-reviewed open-access journals and conference presentations. Following open science principles, anonymized data and metadata will be made publicly available in the Zenodo repository upon study completion.
Trial registration ClinicalTrials.gov (NCT05622539).
Strengths and limitations of this study
- First study to assess the feasibility of integrating an outcome-predictor CDSS into real-life hyperacute stroke workflows, addressing a critical gap between AI model development and clinical implementation
- Multicenter, prospective observational time-motion shadow-mode design, which minimizes interference with standard care while capturing real-world operational data
- Validation of a locked AI model developed from independent retrospective multicenter datasets across different populations, reducing the risk of overfitting to local case-mix
- Real-time data acquisition in the emergency department poses a significant operational challenge, with potential for missing or delayed inputs that may affect model performance in practice
- Risk of bias cannot be excluded, including spectrum bias from non-anticipated subgroups, temporal drift in clinical practice or patient populations, and centre-level variation in workflow and data quality
Competing Interest Statement
Dr Rubiera reported compensation from Bayer for data and safety monitoring services outside the present work. Dr. Lecker received speaker honoraria from IschemaView, Boehringer Ingelheim, Pfizer, Jansen, Biogen, Medtronic and Abbott and advisory board honoraria from Jansen, all outside the submitted work The remaining authors report no disclosures related to the present work.
Clinical Trial
NCT05622539
Clinical Protocols
https://zenodo.org/records/17367485
Funding Statement
This work was supported by the European Commission Horizon Europe Programme grant number 101057263
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Vall Hebron Institut de Recerca gave ethical approval for this work (PR(AG)432-2023); Universitaet Heidelberg Ethikkommission der Med. Fakultaet gave ethical approval for this work (S-687/2023) and Helsinki Committee (Institutional Review Board) of Hadassah Medical Center-Ein Kerem gave ethical approval for this work (HMO-0529-22)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Results will be disseminated through peer-reviewed open-access journals and conference presentations. In line with open science principles, anonymized data and metadata will be made publicly available in the Zenodo repository upon study completion. The analytical code will be available after the future publication of the algorithms.
